Status:
COMPLETED
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Insomnia
Eligibility:
All Genders
21-50 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
Eligibility Criteria
Inclusion
- Healthy subjects with no medical, psychiatric or current sleep disorders.
- Subject must sign a written consent form.
Exclusion
- Recent history of night shift work or jet lag.
- Prior experience sleeping in a sleep lab environment.
- History of sleep disorders.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
411 Patients enrolled
Trial Details
Trial ID
NCT00291187
Start Date
February 1 2006
End Date
August 1 2006
Last Update
October 15 2014
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Birmingham, Alabama, United States
2
Vanda Investigational Site
Phoenix, Arizona, United States
3
Vanda Investigational Site
San Diego, California, United States
4
Vanda Investigational Site
San Francisco, California, United States